Key Takeaways
- 22% revenue growth in a flat market: Revenue grew 22% YoY in Q2 and H1 FY25 while IPM volume growth was just 0.4%, driven by trade generics, institutional expansion, and steady CDMO execution.
- Injectable facility is producing but not yet selling: Commercial batches are manufactured and stored as finished goods; revenue begins in Q3 as each product clears its three-month stability testing, so the margin drag from operating costs without revenue persists for one more quarter.
- PAT margin optically depressed by non-cash depreciation: The injectable facility uses the WDV depreciation method, so 95% of the depreciation increase is from injectables, a non-cash hit concentrated in early years.
- Capacity build-out targets Rs. 1,000 crore revenue: Plant-2 expansion goes fully operational in Q3, a brownfield Plant-6 was acquired in Selaqui, and together they aim to support Rs. 1,000 crore of revenue.
- What to watch next quarter: The pace of injectable revenue ramp as stability batches clear product by product, the CAPEX estimate for Plant-6, and whether EBITDA margin expansion of 2-3% begins to materialize once injectable revenue starts flowing.
Injectable Facility: The Revenue Is in the Warehouse
- Commercial production underway: The injectable facility is already manufacturing against received purchase orders, but finished batches cannot be sold until each product completes three months of stability testing, a regulatory requirement that gates revenue recognition product by product.
- Revenue timeline: A small portion of revenue will come in Q3, with more in Q4; management declined to quantify the ramp and asked investors to evaluate the injectable business only at year-end because OPEX varies with capacity utilization, production volume, and even outside temperatures affecting cooling power consumption.
- Customer validation is strong: Customer audits have yielded very positive reviews, and purchase orders are in hand, but larger customers have their own facility approval processes that take time. The timeline is tracking exactly where management expected.
- Margin drag is real but temporary: The injectable facility's operating costs are already hitting EBITDA while revenue sits in finished goods inventory; this is the primary reason EBITDA margins are flattish YoY despite a favorable business mix shift. Management committed to driving operating leverage sooner rather than later but declined to disclose dosage-form-wise OPEX, calling it a competitive issue.
- Expansion will wait for peak utilization: Space is already available for injectable expansion, but management will not rush it until the existing facility reaches peak capacity, a timeline they say is difficult to predict given uncertainty around injectable revenue numbers.
Hitesh Windlass: "We have got very, very good and very strong positive reviews from customer audits that have happened. And we have already purchased orders against which we are manufacturing just because we cannot sell before the stability data is finished."
Trade Generics & Institutional: The Growth Engine
- Outsized growth in a stagnant IPM: Trade generics and institutional verticals propelled the 22% revenue growth despite industry volume growth of only 0.4%; management argues IQVIA data undercounts the trade generics market, so the stagnation figure may be misleading.
- Growth is internally driven: Expansion levers include entering new geographies, adding stockists, widening the product portfolio, and growing the business development team. The external market opportunity is large, and as the smallest listed player, Windlas sees no structural ceiling on growth.
- Lumpiness is inherent: Quarter-on-quarter variations are expected given the nature of the trade generics business, but the multi-quarter trend over the last 6-7 quarters has been consistently strong.
- Schedule M tailwind: Management predicted Schedule M's passage 2.5-3 years ago at the time of listing, arguing it would pressure a fragmented industry of 13,000 contract manufacturers toward organized players. That consolidation thesis is now playing out as clients make better sourcing decisions.
- Long-term ambition is unbounded: Management sees no reason the trade generics segment should stay small and believes even Rs. 500 crore is not a ceiling, though no timeline was committed.
Hitesh Windlass: "Does India need 13,000 players? I don't think so. No other country in the world has this kind of a fragmented contract manufacturing industry in pharma."
CDMO & Exports: Steady Contribution
- CDMO grew 16% YoY in Q2 and 19% in H1: Growth was driven by improved customer engagement and service levels; most CDMO business operates on an open cost sheet basis, insulating margins from API price erosion.
- Exports surged 35% YoY in Q2 and 26% in H1: The company continues to explore new markets for global demand, though exports remain a smaller portion of the overall mix.
- API price erosion is stabilizing: The impact has already flowed through revenue numbers, and management expects stabilization going forward. Windlas sources mostly domestically, so it is less exposed to import volatility; post-COVID, domestic API manufacturers stepped in, leading to some price erosion that is now settling into a stable regime.
Capacity Expansion: Building Toward Rs. 1,000 Crore
- Plant-2 expansion nears completion: Rs. 26 crore had been spent by September-end, and some machines were already deployed in Q2, meaning Q2 revenue already reflects partial capacity addition. Full operational status is expected in Q3 FY25.
- Plant-6 acquired in Selaqui, Dehradun: A brownfield facility was shortlisted and acquired to meet further capacity needs; refurbishment and validation are expected around Q1 or Q2 FY26. CAPEX estimates are still being scoped and will be shared next quarter.
- Combined revenue target: Plant-2 expansion plus Plant-6 should support revenue of approximately Rs. 1,000 crore. The next site addition would be triggered only when Plant-6 and Plant-2 extension reach 45-50% capacity utilization.
- FY26 CAPEX outlook: Beyond maintenance CAPEX of Rs. 10-15 crore and whatever portion of Plant-6 spend falls in FY26, no other large CAPEX is expected.
Margins & Costs: The Moving Parts
- EBITDA margin was flattish YoY despite favorable mix shift: The injectable facility's operating costs are in the P&L while its revenue is not, offsetting the benefit of a richer business mix. Management expects 2-3% EBITDA margin improvement going forward.
- PAT margin decline is optically worse than reality: Higher depreciation from the injectable facility uses the WDV method, so 95% of the depreciation increase is from injectables and concentrated in early years; this is a non-cash item.
- Employee costs stepped up on multiple fronts: Increases include injectable personnel costs, a 25% minimum wage hike in Uttarakhand, annual increments, and production-linked increases. Management characterized this as a good base going forward.
- Finance cost increase is neutral at the net level: The company uses its cash credit line for interim working capital instead of drawing down bank deposits, so interest income earned on investments roughly offsets the finance cost; there is no net profitability impact.
- R&D spend appears lower but pipeline is unchanged: The decline is purely due to the periodic timing of clinical trials and stability batches; portfolio planning and pipeline richness remain strong.
Capital Allocation: Acquisition Hunt with Patience
- Acquisition mandate is dosage-form expansion: The brief to investment bankers covers ointments, soft gels (a form Windlas currently lacks), protein powders, nutraceutical dosage forms, and hormones. Each expansion should serve all three verticals: CDMO, exports, and trade generics.
- Cash is not a constraint: The company has cash on hand and good debt-taking capacity, and is ready for a larger acquisition. However, management emphasized it will not rush or act out of desperation; if no good fit is found by the time the injectable business is fully set up, it will build a new dosage-form facility on its own.
- Dossier acquisitions underway: A few dossiers have been acquired and the transfer process is ongoing, adding to the product pipeline.
Komal Gupta: "We have been looking for the acquisition possibilities... we don't want to rush it, we don't want to be too desperate. If we see issues, we back off."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable revenue commencement | Revenue begins as stability batches clear product by product; small portion in Q3, more in Q4 | Q3 FY25 onward |
| Plant-2 expansion fully operational | Expansion complete and contributing | Q3 FY25 |
| Plant-6 refurbishment and validation | Brownfield facility ready for production | Q1 or Q2 FY26 |
| Plant-6 CAPEX estimate | Management to provide estimated CAPEX | Next quarter |
| EBITDA margin improvement | 2-3% growth in EBITDA margins expected | Not specified |
| Revenue capacity target | Plant-2 expansion plus Plant-6 to support Rs. 1,000 crore revenue | When both facilities are operational |
| Next site addition trigger | When Plant-6 and Plant-2 extension reach 45-50% capacity utilization | Conditional on utilization |
| Injectable business evaluation | Management requests evaluation at year-end due to OPEX variability | End of FY25 |
| FY26 CAPEX beyond maintenance and Plant-6 | No other big CAPEX requirement | FY26 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹187 crores, +22% YoY |
| H1 FY25 Revenue | ₹362 crores, +22% YoY |
| EBITDA | ₹23 crores, +23% YoY |
| H1 FY25 EBITDA | ₹44 crores, +23% YoY |
| PAT | ₹16 crores, +12% YoY |
| H1 FY25 PAT | ₹29 crores, +12% YoY |
| EPS | ₹7.49 in Q2 FY25, +11% YoY; ₹13.97 in H1 FY25 |
| CDMO vertical revenue | ₹136.3 crores, +16% YoY |
| Trade generics and institutional revenue | ₹41.9 crores, +48% YoY |
| Exports revenue | ₹8.8 crores, +35% YoY |
| Liquidity position | ₹200 crores as on 30th September 2024, after ₹48 crores CAPEX in H1 |
| H1 FY25 CAPEX | ₹48 crores incurred, ₹38 crores cash outflow |
| Plant-2 expansion total CAPEX | ₹33-34 crores, of which ₹26 crores spent by September end |
| Plant-6 acquisition cost | ₹17 crores incurred |
| Dividend paid | ₹5.5 per share, amounting to ₹11.5 crores for FY24, paid in October 2024 |